Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC 716051) for Primary and Recurrent Operable Malignant Gastrointestinal Stromal Tumors Expressing the KIT Receptor Tyrosine Kinase (CD117)

Protocol Documents 

Protocol-RTOG 0132/ACRIN 6665 Amendment 9, 9.10.07 [PDF]

SOC-RTOG 0132/ACRIN 6665 Amendment 9, 9.10.07 [PDF]

Informed Consent-RTOG 0132/ACRIN 6665 [DOC]

Principal Investigators: Burton Eisenberg, MD, RTOG Study Chair
                                       Annick Van den Abbeele, MD, ACRIN Principal Investigator 

Status: Accrual Complete; Primary-Aim Paper in Process

Main Objective: To provide a comprehensive evaluation of the effects of STI-571 on malignant GIST.

Participants: Individuals with a biopsy-proven diagnosis of potentially resectable primary or recurrent malignant gastrointestinal stromal tumor (GIST) or visceral or intraabdominal origin. There must be immunohistochemical documentation of KIT (CD117) expression in the tumor.